Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Vimian Group AB ( (SE:VIMIAN) ).
Vimian Group reported a solid start to 2026, with first-quarter revenue rising 8 per cent to EUR 116.0 million, driven by 9 per cent organic growth and contributions from acquisitions, partly offset by negative currency effects. Profitability improved as EBITA grew 29 per cent to EUR 27.4 million and profit for the period more than doubled to EUR 10.1 million, although the adjusted EBITA margin edged down to 25.2 per cent.
Operating cash flow strengthened by 35 per cent to EUR 23.0 million, supporting the group’s financial flexibility and growth agenda. Management changes saw the CFO, Carl-Johan Zetterberg Boudrie, step in as interim Head of Specialty Pharma and the appointment of Lotta Lundaas as Head of MedTech, moves that could influence execution across its key business segments.
The most recent analyst rating on (SE:VIMIAN) stock is a Sell with a SEK25.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB operates in the animal health sector, providing products and services across specialty pharmaceuticals and medical technology for veterinary care. The company focuses on innovative treatments and devices for companion and production animals, positioning itself as a consolidator in a fragmented global veterinary market.
Average Trading Volume: 299,245
Technical Sentiment Signal: Hold
Current Market Cap: SEK15.02B
For detailed information about VIMIAN stock, go to TipRanks’ Stock Analysis page.